190 related articles for article (PubMed ID: 33811036)
1. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Bertrand D; Verschueren P
Ann Rheum Dis; 2021 Aug; 80(8):965-973. PubMed ID: 33811036
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
[TBL] [Abstract][Full Text] [Related]
4. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
6. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
[TBL] [Abstract][Full Text] [Related]
7. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial.
Pazmino S; Boonen A; De Cock D; Stouten V; Joly J; Bertrand D; Westhovens R; Verschueren P
RMD Open; 2021 May; 7(2):. PubMed ID: 34031262
[TBL] [Abstract][Full Text] [Related]
8. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
[TBL] [Abstract][Full Text] [Related]
9. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
10. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
12. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
de Jong PH; Hazes JM; Han HK; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; van Schaeybroeck B; de Sonnaville PB; van Krugten MV; Luime JJ; Weel AE
Ann Rheum Dis; 2014 Jul; 73(7):1331-9. PubMed ID: 24788619
[TBL] [Abstract][Full Text] [Related]
13. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
14. Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
van Ouwerkerk L; Verschueren P; Boers M; Emery P; de Jong PHP; Landewé RB; Lems W; Smolen JS; Huizinga TW; Allaart CF; Bergstra SA
Ann Rheum Dis; 2024 Jan; 83(1):65-71. PubMed ID: 37607810
[TBL] [Abstract][Full Text] [Related]
15. Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
Jain S; Dhir V
Ann Rheum Dis; 2023 Jul; 82(7):e162. PubMed ID: 34193404
[No Abstract] [Full Text] [Related]
16. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P
Clin Rheumatol; 2020 Sep; 39(9):2593-2601. PubMed ID: 32166429
[TBL] [Abstract][Full Text] [Related]
19. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
[TBL] [Abstract][Full Text] [Related]
20. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
